ClinicalTrials.gg
WithdrawnNCT05156827Updated Jan 12, 2024

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke

A Phase 2 interventional study of TB006 and Placebo in Acute Ischemic Stroke, sponsored by TrueBinding, Inc.. Withdrawn. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-01-12.

Sponsored by TrueBinding, Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This multi-center, randomized, parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of TB006 in participants with an Acute Ischemic Stroke (AIS) event with 57 days of treatment.

02

Conditions studied

  • Acute Ischemic Stroke

Keywords

  • Acute Ischemic Stroke (AIS)
  • TB006
  • stroke
  • efficacy
  • safety
  • pharmacokinetics
  • ischemia
03

In context

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Lead sponsor

TrueBinding, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18 and 40 kilograms per meters squared (kg/m\^2), inclusive
  • Clinical diagnosis of AIS in anterior circulation, supported by evidence of a new stroke on acute brain computed tomography (CT) or magnetic resonance imaging (MRI) consistent with the clinical diagnosis.
  • Able to be randomized and dosed within 7 days of index stroke event. The last known awake time will be used for participants whose stoke occurred during sleep.
  • National Institute of Health Stroke Scale total score of 7 to 21, inclusive
  • Participants may have received standard of care therapy including recombinant tissue plasminogen activator (r-tPA), thrombectomy, mannitol, hypertonic saline, and other treatments per local guidelines as determined by the Investigator. Participants who have received r-tPA within the first day of their stroke event are eligible. However, study drug administration must begin more than 24 hours following r-tPA administration.

Exclusion criteria

Exclusion Criteria:

  • Evidence of severe stroke on imaging (e.g., sulcal effacement or blurring of gray-white junction in greater than 1/3 of middle cerebral artery [MCA] territory, Alberta Stroke Program Early CT [ASPECT] score of 0 to 4 based on head CT, acute infarct volume on MRI diffusion weighed imaging ≥70 mL based on acute imaging studies performed under the standard of care
  • Lacunar or isolated brainstem or cerebellar stroke based on clinical assessment and available acute imaging studies performed under the standard of care
  • Evidence of seizure at the onset of index stroke
  • Evidence of acute myocardial infarction (MI) at Baseline, including any of the following:

    1. Acute ST elevation MI;
    2. Acute decompensated heart failure, or Class III/IV heart failure;
    3. Admission for an acute coronary syndrome, MI, cardiac arrest, or non-voluntary coronary intervention (percutaneous coronary intervention or coronary artery surgery) within the past 3 months.
    4. corrected using Bazett's formula (QTcB) >520 milliseconds (msec).
  • Evidence of acute intracranial or subarachnoid hemorrhage or evidence of active bleeding based on acute brain CT or MRI performed under the standard of care. However, petechial hemorrhages of ≤ 1 centimeter (cm) are not exclusionary.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TB006

    Participants will receive intravenous (IV) 3 infusions of 4000 milligrams (mg) TB006, one every 28 days (Q28D).

    Drug: TB006

  • Placebo comparator
    Placebo

    Participants will receive an IV infusion of normal saline 500 milliliters (mL) Q28D.

    Drug: Placebo

Interventions

  • DrugTB006

    TB006 diluted in normal saline, administered through IV infusion over an hour

  • DrugPlacebo

    Normal saline administered through IV infusion over an hour

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Recovery Success Measured by modified Rankin Scale (mRS) score of 0-1 on the final mRS assessment.

    The Modified Rankin Scale (mRS) measures neurological disability or dependence of participants with stroke on a scale of 0 to 6 and scores indicate the following: 0 - No symptoms; 1 - No significant disability; 2 - Slight disability; 3 - Moderate disability; 4 - Moderately severe disability; 5 - Severe disability; 6 - Dead. Higher score indicates worse condition.

    Time frame: Day 90

Secondary outcomes

  1. Percentage of Participants with Clinically Significant Improvement on the National Institutes of Health Stroke Scale (NIHSS)

    Clinically significant improvement is defined as a 4-point decrease on the NIHSS

    Time frame: At Days 29, 57 and 85

  2. Change from Baseline in Neurological Function on the NIHSS

    The NIHSS is composed of 11 items, each of which rates a specific parameter of ability or function. Each item is rated on a scale of 0 to 4. A score of 0 indicates normal function, with higher scores indicating greater degree of impairment. The individual item scores are added to calculate the NIHSS total score. The minimum score being a 0 (no impairment) and maximum possible score is 42 (death). Higher scores indicate worse condition.

    Time frame: Baseline and through Day 85

  3. Percentage of Participants with Clinically Significant Improvement on the mRS

    Clinically Significant Improvement is defined as 1-point decrease on the mRS

    Time frame: At Days 29, 57 and 85

  4. Change from Baseline in the Montreal Cognitive Assessment (MoCA) Total Score

    The MoCA is a brief screening instrument designed to assess mild cognitive impairment in a variety of participant conditions. The MoCA assesses eight cognitive domains: visuospatial ability, executive function, short-term memory recall, attention, concentration, working memory, language, and orientation to time and space. Scores on the MoCA range from 0 to 30, with lower scores indicating greater impairment.

    Time frame: Baseline and at Days 29, 57, and 85

  5. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Day 141

  6. Number of Participants with Clinically Significant Clinical Laboratory Parameter Values

    Time frame: Up to Day 141

  7. Number of Participants with Clinically Significant Vital Sign Values

    Time frame: Up to Day 141

  8. Number of Participants with Clinically Significant 12-Lead Electrocardiogram Findings

    Time frame: Up to Day 141

  9. Number of participants with Columbia Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. For each of the 5 items of the C-SSRS related to suicidal ideation intensity, an individual's degree of suicidal ideation is rated on a 0-5 scale with 0: no suicidal behavior and 5: active suicidal ideation. The total score is the sum of the 5 intensity item scores (total score ranges from 0 to 25). Higher scores in the scale indicate greater disease severity.

    Time frame: Up to Day 141

  10. Number of Participants with Clinically Significant Physical Examination Findings

    Time frame: Up to Day 141

  11. Number of Participants with Anti-drug Antibodies

    Time frame: Up to Day 141

  12. Plasma concentration of TB006

    Time frame: Pre-dose and post-dose on Days 1, 29, 57, 85 and 141

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Dec 2023, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2021
First posted
Dec 14, 2021
StartActual
Jul 26, 2022
Primary completionActual
Dec 18, 2023
CompletionActual
Dec 18, 2023
Last update
Jan 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05156827
Lead sponsor
TrueBinding, Inc.
Responsible party
Sponsor
First posted
Dec 14, 2021
Start date
Jul 26, 2022
Primary completion
Dec 18, 2023
Completion
Dec 18, 2023
Last update
Jan 12, 2024

Study contacts

TrueBinding, Inc.
study director · TrueBinding, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TB006

Start the discussion